Vaginal Cancer: Symptoms, Diagnosis, Treatment, and Care

Vaginal cancer is a rare gynecologic cancer that starts in the vagina—the muscular
canal that connects the cervix (lower uterus) to the outside of the body. Because it is
uncommon and early symptoms can be subtle, many cases are detected during routine
gynecologic exams or evaluation for abnormal bleeding. The encouraging news: when
found early and treated by an experienced, multidisciplinary team, outcomes are often
very good. This comprehensive article on vaginal cancer: what it is, how it;s diagnosed and staged, modern treatments, prevention strategies, recovery and followup at Apollo
Hospitals.

Note: This guide is for general education and does not replace medical advice.
Personal decisions should be made with a qualified gynecologic oncology team.

Overview: What Is Vaginal Cancer and Why Early Detection Matters

Vaginal cancer occurs when cells in the vaginal lining develop DNA changes and begin
to grow uncontrollably. Most cases arise from the squamous cells that line the vagina
and develop slowly through precancerous stages (vaginal intraepithelial neoplasia, or
VaIN). Less commonly, cancers can start in glandular cells (adenocarcinoma),
pigmentproducing cells (melanoma), or connective tissue (sarcoma).

There’s no routine screening test specifically for vaginal cancer; regular
gynecologic visits help pick up problems early even when you feel well.

Why early detection matters:

•  Precancer (VaIN) can be treated before it becomes cancer.
•  Earlystage vaginal cancer is highly treatable and often curable with limited
  surgery or focused radiation
•  Prompt diagnosis reduces the need for more intensive treatment and helps
  preserve vaginal form and function.
  How common is it?
•  Vaginal cancer is rare compared with cervical or endometrial cancer, most often
  affecting people over age 60. Some subtypes occur in younger individuals.

Types of Vaginal Cancer

Understanding the cell type helps guide treatment and prognosis.

•  Squamous cell carcinoma (most common)
  o Often linked to persistent highrisk human papillomavirus (HPV) infection.
  o Typically develops in the upper third of the vagina near the cervix.
• Adenocarcinoma
  o Includes clear cell adenocarcinoma (rare; historically associated with
  prenatal diethylstilbestrol [DES] exposure) and other glandtype cancers.
•  Melanoma of the vagina (rare)
  o Arises from pigmentproducing cells; can occur on the vaginal wall or
  introitus (vaginal opening).
•  Sarcomas (rare)
  o Leiomyosarcoma, rhabdomyosarcoma, and others; more common in
  children/teens for certain subtypes (e.g., botryoid rhabdomyosarcoma).
•  Vaginal intraepithelial neoplasia (VaIN)
  o Precancerous changes (VaIN 1–3); treatable and monitored to prevent
  progression.

•  Persistent highrisk HPV infection (notably types 16 and 18). HPV is
  common and spread by skin-to-skin intimate contact; vaccination lowers
  the chance of HPV-related precancers and cancers over time.
•  Agerelated cellular changes
•  Chronic inflammation, irritants, or previous radiation to the pelvis
•  DES exposure in utero (historical; linked to clear cell adenocarcinoma).
  This is uncommon today; although risk persists into adulthood, clear-cell
  cancers remain rare.
•  Rare genetic or immune factors that reduce the body’s ability to clear HPVMost people with vaginal cancer have done nothing to “cause” it. HPV is common and
  spread by intimate skintoskin contact; prevention focuses on vaccination and regular
  screening.

Risk Factors: Who Is at Higher Risk?

•  Persistent highrisk HPV infection
•  History of cervical precancer/cancer, or VaIN
•  Age over 60 (risk increases with age)
•  Smoking (reduces local immune function, raises HPVrelated cancer risk)
•  Immunosuppression (HIV infection, longterm immunosuppressants)
•  Prior pelvic radiation therapy
•  In utero DES exposure (for clear cell adenocarcinoma; rare today)Reducing modifiable risks—especially HPV vaccination, smoking cessation, and routine
  gynecologic care—can help lower risk.

What Are the Symptoms of Vaginal Cancer?

Because there’s no standard screening test for vaginal cancer, please seek care if
symptoms such as bleeding or persistent discharge last more than 2–3 weeks.

Common early signs:

•  Abnormal vaginal bleeding (after sex, between periods, or after menopause)
•  Watery, bloodtinged, or foulsmelling discharge
•  Pain during sex (dyspareunia) or bleeding after intercourse
•  A palpable mass or thickening in the vagina

Advanced symptoms:

•  Pelvic pain or pressure
•  Painful urination or difficulty passing urine
•  Constipation or blood in stool if nearby structures are affected
•  Swelling in the legs if lymphatic drainage is blockedAny new bleeding after menopause or persistent abnormal discharge should be
  evaluated promptly.

How Is Vaginal Cancer Diagnosed?

Diagnosis confirms the presence of cancer, defines its extent, and guides treatment
planning.

•  Medical history and pelvic examination
  o Review of symptoms, prior abnormal Pap/HPV tests, cervical/vaginal
  treatments, smoking, and immune status.
  o Speculum and bimanual exam to visualize and palpate the vaginal walls
  and cervix.
•  Colposcopy
  o A magnified exam using acetic acid and Lugol’s iodine to highlight
  abnormal areas.
  o Directed biopsies taken from suspicious sites.
•  Biopsy (key step)
  o Confirms cancer type (squamous, adenocarcinoma, melanoma, sarcoma)
  and grade.
  o For submucosal masses, core biopsy may be used.
•  Imaging for staging
  o MRI pelvis: best for mapping tumor size, depth, and involvement of the
  vaginal wall, urethra, bladder, rectum, and pelvic sidewall.
  o CT or PETCT: assesses lymph nodes and distant spread (lungs, liver).
  o If the cancer appears to start at the very top of the vagina and
  extends into the cervix, AJCC classifies this as a cervical
  cancer—your team will label it correctly so you get the right
  treatment.
  o Cystoscopy or proctoscopy: if symptoms suggest bladder or rectal
  involvement.
•  Laboratory tests
  o Complete blood count and organ function tests to plan safe therapy.
  o HIV testing may be recommended in some cases for comprehensive care.

Staging and Grading: What They Mean

Staging (FIGO) reflects how far the cancer has spread:

•  Stage I: Confined to the vaginal wall.
•  Stage II: Involves subvaginal tissue (paravaginal) but not the pelvic wall.
•  Stage III: Has reached the pelvic wall and/or the lower vagina, and/or blocks
  kidney drainage (hydronephrosis); it may have spread to nearby lymph
  nodes.
• Stage IV: Invades bladder/rectum (IVA) or has spread to distant organs
  (IVB).

Doctors often document both FIGO stage and TNM details (tumor size, node
status) to guide therapy.
Grading describes how abnormal the cells look and how fast they may grow (low,
intermediate, high grade). Histology (squamous vs others) also influences behavior and
treatment.

Why this matters:

•  Stage, grade, and histology drive the treatment approach (surgery vs
  radiationbased vs multimodal).
•  Imaging findings help determine radiation fields and eligibility for organsparing
  strategies.

Treatment Options for Vaginal Cancer

Treatment is tailored by stage, tumor size and location, histology, age, overall health,
and personal goals. A multidisciplinary team—gynecologic oncologists, radiation
oncologists, medical oncologists, radiologists, pathologists, urologists/colorectal
surgeons (when needed), physiotherapists, and supportive care
specialists—collaborates to optimize outcomes and quality of life.

Surgery
Surgery plays a larger role for small, earlystage tumors in accessible locations.

•  Local excision or partial vaginectomy
  o Removes the tumor with a margin of healthy tissue; often for small Stage I
  lesions.
  o Reconstruction (local advancement flaps or grafts) may maintain anatomy
  and function.
• Radical vaginectomy (select cases)
  o Removes a larger portion or all of the vagina for more extensive tumors;
  may be combined with hysterectomy and lymph node evaluation.
• Lymph-node evaluation depends on tumor location (pelvis for upper
  vagina; groin for lower third). Use of sentinel lymph node mapping alone
  isn’t yet established in vaginal cancer.
• Multidisciplinary surgery
  o If adjacent organs are involved (bladder/rectum), coordinated procedures
  may be required in advanced, highly selected cases.Surgery is carefully balanced with radiation options to preserve function whenever
  possible.

Medical Treatment

•  Chemotherapy
  o Weekly cisplatin with radiation is commonly used, based largely on
  experience from cervical cancer. High-quality evidence specific to
  vaginal cancer is limited, but this approach can improve local
  control.
•  Targeted therapy
  o Limited proven roles in primary vaginal squamous cancers; may be
  considered for specific molecular profiles in rare histologies or recurrent
  disease.
•  Immunotherapy
  o Consider in selected recurrent/metastatic cases—ideally in a clinical
  trial or when specific biomarkers are present. Data remain limited in
  vaginal cancer.
•  Supportive care
  o Pain control, infection management, nutrition support, sexual health
  counseling, and pelvic floor therapy.

Radiation Therapy
Radiation is central for many patients and can be curative, organsparing therapy.

•  External beam radiation therapy (EBRT)
  o Treats the pelvis and regional lymph nodes with highly conformal
  techniques such as IMRT/IGRT to spare bowel, bladder, and bone
  marrow.
  o Field selection depends on tumor location (upper vs lower vagina) and
  nodal drainage patterns (pelvic vs inguinal nodes).
• Brachytherapy (internal radiation)
  o Delivers a high dose directly to the vaginal tumor/bed using intracavitary
  applicators (for superficial lesions) or interstitial needles (for thicker/deeper
  tumors).
  o Essential for dose escalation while limiting exposure to surrounding
  tissues.
• Stereotactic techniques
  o For limited metastases or difficult recurrences, stereotactic
  radiotherapy may be considered case-by-case.

Side effects may include temporary fatigue, skin irritation, diarrhea, bladder urgency,
and, over time, vaginal dryness or narrowing (stenosis). A prevention and rehabilitation
plan (dilators, moisturizers, pelvic floor therapy) is key.

Proton Therapy

Proton therapy may help in re-irradiation or unusual anatomy to spare healthy
organs, but most patients do very well with advanced photon IMRT/IGRT plus
brachytherapy. Suitability is individualized at experienced centers.

Prognosis: Survival, Function, and What Influences Outcomes

•  Earlystage disease (Stage I) has a favorable outlook, with high local control rates
  using surgery or chemoradiation.
•  Stage, tumor size/thickness, nodal status, and completeness of local therapy
  (including brachytherapy when indicated) markedly influence outcomes.
•  Histology matters: squamous carcinomas typically respond well to radiation;
  melanoma and sarcomas follow different protocols and prognoses.
•  Smoking cessation, nutrition, and pelvic rehabilitation improve recovery and
  longterm function.
•  With modern multidisciplinary care, many people maintain meaningful sexual
  function and quality of life.

Screening and Prevention: How to Lower Risk and Catch Problems Early

•  HPV vaccination
  o Strongly recommended where eligible; it lowers the risk of HPV-
  related vaginal/vulvar precancers and cancers over time.
• Routine gynecologic care
  o There’s no standard screening test specifically for vaginal cancer;
  pelvic exams help detect problems early. Continue cervical
  screening (Pap/HPV) as advised for cervical health.
• Smoking cessation
  o Improves immune health and reduces HPVrelated cancer risks; also
  enhances treatment outcomes.
• Prompt evaluation
  o Seek assessment for abnormal bleeding, persistent discharge/odor, pain
  during sex, or a palpable mass.
• Healthy lifestyle
  o Balanced nutrition, physical activity, sleep, and stress management
  support immune function and recovery.

For International Patients: Seamless Access and Support at Apollo

Apollo Hospitals provides coordinated, patientcentered services to help international
patients start care quickly and confidently:

•  Prearrival medical review
  o Secure sharing of reports for a preliminary opinion and tentative plan to
  aid travel and budgeting.
•  Appointment and treatment coordination
  o Priority scheduling with gynecologic oncology, radiation oncology
  (including advanced IMRT/IGRT and brachytherapy planning), medical
  oncology, radiology, pathology, urology/colorectal surgery (as needed),
  rehabilitation, and supportive care.
• Travel and logistics
  o Assistance with medical visa invitations, airport pickup on request, nearby
  accommodation guidance, and local transportation help.
• Language and cultural support
  o Interpreter services, written care plans, and patient navigators for clear,
  compassionate communication.
• Financial counseling
  o Transparent estimates, package options where feasible, insurance
  coordination, and support with international payments.
• Continuity of care
  o Detailed discharge summaries, survivorship and rehabilitation plans,
  sexual health guidance, and teleconsultations for followup, with
  coordination for homecountry care.

Recovery, Side Effects, and FollowUp: What to Expect

•  After surgery
  o Most recover in days to a few weeks, depending on procedure extent and
  reconstruction.
  o Wound care, pain control, and gradual return to activity are guided by the
  team.
  o Pelvic floor therapy supports continence, comfort, and sexual function.
•  During chemoradiation
  o Common effects: fatigue, skin irritation, bowel/bladder urgency, vaginal
  soreness.
  o Supportive care includes skin care, antidiarrheal or bladder medicines,
  pain control, nutrition, and hydration.
  o Sexual health support, lubricants, and dilator therapy help prevent
  longterm narrowing and maintain comfort.
• Longterm wellness
  o Plan for vaginal health: dilators, moisturizers, and pelvic physiotherapy.
  o Manage menopause symptoms if ovaries are affected by prior treatments.
  o Attend to mental health, body image, and intimacy concerns with
  counseling and peer support.
• Followup schedule
  o Typically every 3–4 (up to 6) months for the first 2 years, then every
  6–12 months to year 5; after that, annual/individualized follow-up.
  o Visits include symptom review, pelvic exam, and imaging/tests as
  indicated.
  o Report new bleeding, discharge, pain, or urinary/bowel changes between
  visits.

Next Steps

•  Arrange a gynecologic evaluation for abnormal bleeding, persistent discharge,
  pain during sex, or a palpable mass.
•  Bring prior Pap/HPV results, biopsy reports, imaging scans, and a current
  medication list to the appointment.
•  Ask about the tumor location and stage, whether surgery or chemoradiation is
  recommended, the role of brachytherapy, sexual health preservation strategies,
  and the followup plan.
•  Discuss HPV vaccination for eligible family members and smoking cessation
  resources if needed.With early recognition, precise imaging, expert surgery and radiation, and
  comprehensive supportive care, many people with vaginal cancer achieve excellent
  control and maintain quality of life. A compassionate, experienced team will guide each
  step—prioritizing cure, function, and longterm wellness.

About Apollo Proton Cancer Centre

Apollo Proton Cancer Centre (APCC) is the first proton therapy centre in India. APCC
has a fully integrated treatment suite that offers the most advanced treatment in
surgical, radiation and medical oncology procedures. True to the Apollo Pillars of
Expertise and Excellence, the Centre brings together a powerful team of clinicians
renowned globally for cancer care.

At Apollo Proton Cancer Centre (APCC), we combine advanced technology with
globally renowned clinical expertise to deliver superior outcomes and improved quality
of life to our patients.